| ￥3500 | |
| Z05733-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 59 kDa (pro-form) and 14 kDa (mature form)&65-68 kDa (pro-form) and 15kDa (mature form) | ||||
| Apparent Molecular Weight | Due to autocatalytic cleavage, the protein release the pro-form (59 kDa) and mature form (14 kDa). Due to glycosylation, the protein migrates to 65-68 kDa (pro-form) and 15kDa (mature form) based on Bis-Tris PAGE result. | ||||
| Formulation | Supplied as 0.22μm filtered solution in 20mM PB, 300mM NaCl, 10% Glycerol (pH 7.4). | ||||
| Concentration | Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford. | ||||
| Storage & Stability | This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles. |
| Target Background | Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated. |
| Synonyms | PC9; PCSK9; FH3; HCHOLA3; LDLCQ1; NARC-1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
